Monday, April 06, 2026 5:39:56 PM
Their contract states they must be able to supply ( not sure how much ) OLC on June 30th , if approved.
So Shilpa will definitely be motivated to keep things on track .
Whether the Indian govt gets involved is something else as theres a severe shortage of propane in the areas Shilpa has manufacturing plants ...and govt has mandated as much propane as possible be diverted to house hold use in those areas.
The risk of a delay obviously is that expected approval gets pushed back and they miss the July TDAPA cut off date ...so burn thru another $3-$4 m .
JMO ..interesting to find the $10m payment to Shilpa on approval and launch ...I'll try and copy and paste it
From Gemini
Yes, Shilpa Medicare Ltd. is reportedly eligible for a $10 million milestone payment from its partner Unicycive Therapeutics (UNCY) related to the filing, approval, and launch of Oxylanthanum Carbonate (OLC).
Key Agreement Details
Milestone Payment: Shilpa Medicare (SML) is expected to receive $10 million in milestone income distributed across the regulatory filing, approval, and eventual product launch of OLC.
Manufacturing Partnership: Shilpa provides end-to-end CDMO services for OLC, including APIs and finished dosage forms.
Commercial Supply: A long-term agreement is in place for Shilpa to meet all commercial requirements for OLC starting in the 2025–26 fiscal year.
Additional Funding: Unicycive is also funding the establishment of a new dedicated manufacturing block at Shilpa's Raichur facility to handle increased demand.
So they are motivated to keep on track
Kiwi
Recent UNCY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:51:50 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 10:30:46 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 11:04:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 11:02:10 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 11:00:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:11:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:29:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 10:32:02 AM
- Unicycive shares gain as FDA accepts resubmitted OLC NDA • IH Market News • 01/29/2026 03:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/14/2025 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 02:12:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:39:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:30:13 AM
- UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit • PR Newswire (US) • 10/14/2025 06:55:00 AM
